絞り込み

16548

広告

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.

著者 Tsourdi E , Makras P , Rachner TD , Polyzos S , Rauner M , Mandanas S , Hofbauer LC , Anastasilakis AD
Bone.2018 Oct 04 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (33view , 0users)

Full Text Sources

Prior osteoporosis therapies may affect the skeletal response to denosumab. We compared the effect of denosumab (60 mg every 6 months for 12 months) on bone mineral density and bone metabolism parameters in postmenopausal women with low bone mass who were either treatment-naïve (n = 30), or previously treated either with zoledronic acid (n = 30), or teriparatide (n = 22).
PMID: 30292818 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード